Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Arai H, et al. Among authors: tsuda t. Cancer Med. 2024 Apr;13(7):e7107. doi: 10.1002/cam4.7107. Cancer Med. 2024. PMID: 38591098 Free PMC article. Clinical Trial.
Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.
Horie Y, Yamazaki K, Funakoshi T, Hamauchi S, Taniguchi H, Tsushima T, Todaka A, Machida N, Taku K, Fukutomi A, Onozawa Y, Yasui H, Mizukami T, Izawa N, Hirakawa M, Tsuda T, Nakajima T, Boku N. Horie Y, et al. Among authors: tsuda t. Mol Clin Oncol. 2015 Sep;3(5):1029-1034. doi: 10.3892/mco.2015.586. Epub 2015 Jun 24. Mol Clin Oncol. 2015. PMID: 26623045 Free PMC article.
Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
Nakajima TE, Boku N, Doi A, Arai H, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Sunakawa Y. Nakajima TE, et al. Among authors: tsuda t. Invest New Drugs. 2020 Apr;38(2):410-418. doi: 10.1007/s10637-019-00782-8. Epub 2019 Apr 24. Invest New Drugs. 2020. PMID: 31020609 Clinical Trial.
Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size.
Sakamaki K, Kito Y, Yamazaki K, Izawa N, Tsuda T, Morita S, Boku N. Sakamaki K, et al. Among authors: tsuda t. ESMO Open. 2017 Nov 14;2(5):e000275. doi: 10.1136/esmoopen-2017-000275. eCollection 2017. ESMO Open. 2017. PMID: 29177097 Free PMC article.
Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T, Kyomori C, Mizukami T, Taniyama T, Izawa N, Horie Y, Hirakawa M, Ogura T, Nakajima TE, Tsugawa K, Boku N. Tsuda T, et al. Mol Clin Oncol. 2016 Apr;4(4):603-606. doi: 10.3892/mco.2016.769. Epub 2016 Feb 5. Mol Clin Oncol. 2016. PMID: 27073673 Free PMC article.
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Sakai D, et al. Among authors: tsuda t. Eur J Cancer. 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32526634 Clinical Trial.
1,627 results